Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lappegård KT[au]:

Search results

Items: 1 to 50 of 71

1.

Telemonitoring and Quality of Life in Patients after 12 Months Following a Pacemaker Implant: the Nordland Study, a Randomised Trial.

López-Liria R, López-Villegas A, Enebakk T, Thunhaug H, Lappegård KT, Catalán-Matamoros D.

Int J Environ Res Public Health. 2019 Jun 5;16(11). pii: E2001. doi: 10.3390/ijerph16112001.

2.

Intensive lipid lowering therapy reduces large, but not small, dense low-density lipoprotein particles measured by gel electrophoresis, in elderly patients with atrial fibrillation.

Kjellmo CA, Pop G, Lappegård KT, Hovland A.

Eur J Prev Cardiol. 2019 Apr 29:2047487319845966. doi: 10.1177/2047487319845966. [Epub ahead of print] No abstract available.

PMID:
31032636
3.

Secular and longitudinal trends in cardiovascular risk in a general population using a national risk model: The Tromsø Study.

Nilsen A, Hanssen TA, Lappegård KT, Eggen AE, Løchen ML, Njølstad I, Wilsgaard T, Hopstock L.

Eur J Prev Cardiol. 2019 Feb 12:2047487319830806. doi: 10.1177/2047487319830806. [Epub ahead of print]

PMID:
30755014
4.

Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4.

Landsem A, Fure H, Krey Ludviksen J, Christiansen D, Lau C, Mathisen M, Bergseth G, Nymo S, Lappegård KT, Woodruff TM, Espevik T, Mollnes TE, Brekke OL.

Clin Exp Immunol. 2019 Apr;196(1):97-110. doi: 10.1111/cei.13240. Epub 2018 Dec 19.

5.

Health-related quality of life on tele-monitoring for users with pacemakers 6 months after implant: the NORDLAND study, a randomized trial.

Lopez-Villegas A, Catalan-Matamoros D, Lopez-Liria R, Enebakk T, Thunhaug H, Lappegård KT.

BMC Geriatr. 2018 Sep 21;18(1):223. doi: 10.1186/s12877-018-0911-3.

6.

Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial.

Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K.

ESC Heart Fail. 2018 Oct;5(5):977-984. doi: 10.1002/ehf2.12332. Epub 2018 Aug 7. Review.

7.

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

Kjellmo CA, Hovland A, Lappegård KT.

Diseases. 2018 May 27;6(2). pii: E45. doi: 10.3390/diseases6020045. Review.

8.

Granulocyte and monocyte CD11b expression during plasma separation is dependent on complement factor 5 (C5) - an ex vivo study with blood from a C5-deficient individual.

Hardersen R, Enebakk T, Christiansen D, Bergseth G, Brekke OL, Mollnes TE, Lappegård KT, Hovland A.

APMIS. 2018 Apr;126(4):342-352. doi: 10.1111/apm.12821.

PMID:
29575196
9.

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.

Lappegård KT, Kjellmo CA, Ljunggren S, Cederbrant K, Marcusson-Ståhl M, Mathisen M, Karlsson H, Hovland A.

Transfus Apher Sci. 2018 Feb;57(1):91-96. doi: 10.1016/j.transci.2018.01.002. Epub 2018 Jan 4.

10.

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.

Kjellmo CA, Karlsson H, Nestvold TK, Ljunggren S, Cederbrant K, Marcusson-Ståhl M, Mathisen M, Lappegård KT, Hovland A.

J Clin Lipidol. 2018 Jan - Feb;12(1):193-202. doi: 10.1016/j.jacl.2017.10.007. Epub 2017 Nov 8.

11.

Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals.

Hovland A, Nestvold T, Bohov P, Trøseid M, Aukrust P, Berge RK, Waage-Nielsen E, Retterstøl K, Lappegård KT.

Scand J Clin Lab Invest. 2017 Dec;77(8):628-633. doi: 10.1080/00365513.2017.1393691. Epub 2017 Oct 25.

PMID:
29069988
12.

Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe.

Bergland Ellingsen S, Nordmo E, Lappegård KT.

Clin Med Insights Case Rep. 2017 Sep 25;10:1179547617731375. doi: 10.1177/1179547617731375. eCollection 2017.

13.

LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.

Lappegård KT, Enebakk T, Thunhaug H, Ludviksen JK, Mollnes TE, Hovland A.

J Clin Lipidol. 2016 Nov - Dec;10(6):1481-1487. doi: 10.1016/j.jacl.2016.09.001. Epub 2016 Sep 13.

PMID:
27919366
14.

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.

Lappegård KT, Enebakk T, Thunhaug H, Hovland A.

Atherosclerosis. 2016 Aug;251:119-123. doi: 10.1016/j.atherosclerosis.2016.06.015. Epub 2016 Jun 9.

PMID:
27318831
15.

Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.

Trøseid M, Hov JR, Nestvold TK, Thoresen H, Berge RK, Svardal A, Lappegård KT.

Metab Syndr Relat Disord. 2016 May;14(4):197-201. doi: 10.1089/met.2015.0120. Epub 2016 Jan 26.

16.

Therapeutic complement inhibition – from experimental to clinical medicine.

Lappegård KT, Bjerre A, Tjønnfjord GE, Mollnes TE.

Tidsskr Nor Laegeforen. 2015 Oct 20;135(19):1745-9. doi: 10.4045/tidsskr.15.0049. eCollection 2015 Oct 20. Review. English, Norwegian.

17.

Gene expression profiling of Gram-negative bacteria-induced inflammation in human whole blood: The role of complement and CD14-mediated innate immune response.

Lau C, Olstad OK, Holden M, Nygård S, Fure H, Lappegård KT, Brekke OL, Espevik T, Hovig E, Mollnes TE.

Genom Data. 2015 May 30;5:176-83. doi: 10.1016/j.gdata.2015.05.019. eCollection 2015 Sep.

18.

Effect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A Review.

Lappegård KT, Bjørnstad H, Mollnes TE, Hovland A.

Scand J Immunol. 2015 Sep;82(3):191-8. doi: 10.1111/sji.12328. Review.

19.

The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis.

Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegård KT, Espevik T, Mollnes TE.

Atherosclerosis. 2015 Aug;241(2):480-94. doi: 10.1016/j.atherosclerosis.2015.05.038. Epub 2015 Jun 5. Review.

20.

CD14 and complement crosstalk and largely mediate the transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray.

Lau C, Nygård S, Fure H, Olstad OK, Holden M, Lappegård KT, Brekke OL, Espevik T, Hovig E, Mollnes TE.

PLoS One. 2015 Feb 23;10(2):e0117261. doi: 10.1371/journal.pone.0117261. eCollection 2015.

21.

Soluble CD14 is associated with markers of vascular dysfunction in bariatric surgery patients.

Trøseid M, Nestvold TK, Nielsen EW, Thoresen H, Seljeflot I, Lappegård KT.

Metab Syndr Relat Disord. 2015 Apr;13(3):119-24. doi: 10.1089/met.2014.0111. Epub 2015 Jan 6.

PMID:
25562385
22.

Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4.

Nestvold TK, Nielsen EW, Ludviksen JK, Fure H, Landsem A, Lappegård KT.

Metab Syndr Relat Disord. 2015 Feb;13(1):29-35. doi: 10.1089/met.2014.0099. Epub 2014 Oct 20.

PMID:
25329451
23.

A vital role for complement in heart disease.

Lappegård KT, Garred P, Jonasson L, Espevik T, Aukrust P, Yndestad A, Mollnes TE, Hovland A.

Mol Immunol. 2014 Oct;61(2):126-34. doi: 10.1016/j.molimm.2014.06.036. Epub 2014 Jul 16. Review.

24.

Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, Lappegård KT, Brekke OL, Lambris JD, Damås JK, Latz E, Mollnes TE, Espevik T.

J Immunol. 2014 Mar 15;192(6):2837-45. doi: 10.4049/jimmunol.1302484. Epub 2014 Feb 19.

25.

Bariatric surgery reduces risk factors for development of type 2 diabetes mellitus in morbidly obese, nondiabetic patients.

Nestvold TK, Nielsen EW, Lappegård KT.

Metab Syndr Relat Disord. 2013 Dec;11(6):441-6. doi: 10.1089/met.2013.0085. Epub 2013 Sep 17.

PMID:
24044780
26.

Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: evidence from bariatric surgery.

Trøseid M, Nestvold TK, Rudi K, Thoresen H, Nielsen EW, Lappegård KT.

Diabetes Care. 2013 Nov;36(11):3627-32. doi: 10.2337/dc13-0451. Epub 2013 Jul 8.

27.

Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.

Lappegård KT, Pop-Purceleanu M, van Heerde W, Sexton J, Tendolkar I, Pop G.

J Neuroinflammation. 2013 Jun 28;10:78. doi: 10.1186/1742-2094-10-78.

28.

Primary complement C5 deficiencies - molecular characterization and clinical review of two families.

Schejbel L, Fadnes D, Permin H, Lappegård KT, Garred P, Mollnes TE.

Immunobiology. 2013 Oct;218(10):1304-10. doi: 10.1016/j.imbio.2013.04.021. Epub 2013 May 14. Review.

PMID:
23743184
29.

Atrial fibrillation: inflammation in disguise?

Lappegård KT, Hovland A, Pop GA, Mollnes TE.

Scand J Immunol. 2013 Aug;78(2):112-9. doi: 10.1111/sji.12061. Review.

30.
31.

LDL apheresis and inflammation--implications for atherosclerosis.

Hovland A, Lappegård KT, Mollnes TE.

Scand J Immunol. 2012 Sep;76(3):229-36. doi: 10.1111/j.1365-3083.2012.02734.x. Review.

32.

Complement profile and activation mechanisms by different LDL apheresis systems.

Hovland A, Hardersen R, Nielsen EW, Enebakk T, Christiansen D, Ludviksen JK, Mollnes TE, Lappegård KT.

Acta Biomater. 2012 Jul;8(6):2288-96. doi: 10.1016/j.actbio.2012.02.017. Epub 2012 Feb 25.

PMID:
22373816
33.

Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles.

Hovland A, Marcovina S, Hardersen R, Enebakk T, Mollnes TE, Lappegård KT.

Transfus Apher Sci. 2012 Feb;46(1):73-6. doi: 10.1016/j.transci.2011.11.016. Epub 2011 Dec 27.

PMID:
22206792
34.

Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment.

van Kuilenburg J, Lappegård KT, Sexton J, Plesiewicz I, Lap P, Bouwels L, Sprong T, Mollnes TE, Verheugt F, van Heerde WL, Pop GA.

J Clin Lipidol. 2011 Jul-Aug;5(4):273-80. doi: 10.1016/j.jacl.2011.05.003. Epub 2011 May 20.

PMID:
21784372
35.

Pacemaker implantation in small hospitals: complication rates comparable to larger centres.

Haug B, Kjelsberg K, Lappegård KT.

Europace. 2011 Nov;13(11):1580-6. doi: 10.1093/europace/eur162. Epub 2011 Jun 28. Review.

36.

Ivabradine and nightmares: a previously unreported adverse reaction.

Lappegård KT, Nordmo E.

Eur J Clin Pharmacol. 2011 Dec;67(12):1313-4. doi: 10.1007/s00228-011-1085-5. Epub 2011 Jun 24. No abstract available.

PMID:
21701883
37.

Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient-a case report.

Grimnes G, Beckman H, Lappegård KT, Mollnes TE, Skogen V.

APMIS. 2011 Jul;119(7):479-84. doi: 10.1111/j.1600-0463.2011.02740.x. Epub 2011 Apr 8.

PMID:
21635555
38.

Patient tolerance regarding different low-density lipoprotein apheresis columns: frequent minor side effects and high patient satisfaction.

Hovland A, Hardersen R, Enebakk T, Mollnes TE, Lappegård KT.

J Clin Lipidol. 2011 Jan-Feb;5(1):45-9. doi: 10.1016/j.jacl.2010.11.003. Epub 2010 Nov 18.

PMID:
21262506
39.

Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.

Bergseth G, Lambris JD, Mollnes TE, Lappegård KT.

Ann Thorac Surg. 2011 Feb;91(2):527-33. doi: 10.1016/j.athoracsur.2010.10.084.

40.

No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins.

Hovland A, Aagnes I, Brekke OL, Flage JH, Lappegård KT.

J Clin Lipidol. 2010 Jul-Aug;4(4):288-92. doi: 10.1016/j.jacl.2010.02.011. Epub 2010 Jun 1.

PMID:
21122661
41.

Induction of ventricular tachycardia by alternate current due to an insufficiently grounded electrical system.

Lappegård KT.

Pacing Clin Electrophysiol. 2012 Jun;35(6):e170-2. doi: 10.1111/j.1540-8159.2010.02964.x. Epub 2010 Nov 17.

PMID:
21091734
42.

Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia.

Hovland A, Hardersen R, Mollnes TE, Lappegård KT.

JOP. 2010 Sep 6;11(5):467-9.

43.

Hematologic and hemostatic changes induced by different columns during LDL apheresis.

Hovland A, Hardersen R, Nielsen EW, Mollnes TE, Lappegård KT.

J Clin Apher. 2010;25(5):294-300. doi: 10.1002/jca.20256.

PMID:
20806414
44.

Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies.

Hellerud BC, Aase A, Herstad TK, Naess LM, Kristiansen LH, Trøseid AM, Harboe M, Lappegård KT, Brandtzaeg P, Høiby EA, Mollnes TE.

Infect Immun. 2010 Feb;78(2):802-9. doi: 10.1128/IAI.01044-09. Epub 2009 Nov 23.

45.

Different inflammatory responses induced by three LDL-lowering apheresis columns.

Hovland A, Hardersen R, Sexton J, Mollnes TE, Lappegård KT.

J Clin Apher. 2009;24(6):247-53. doi: 10.1002/jca.20223.

PMID:
19927364
46.

The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome.

Trøseid M, Lappegård KT, Mollnes TE, Arnesen H, Seljeflot I.

Metab Syndr Relat Disord. 2009 Dec;7(6):579-84. doi: 10.1089/met.2009.0003.

PMID:
19900154
47.

Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature.

Lappegård KT, Christiansen D, Pharo A, Thorgersen EB, Hellerud BC, Lindstad J, Nielsen EW, Bergseth G, Fadnes D, Abrahamsen TG, Høiby EA, Schejbel L, Garred P, Lambris JD, Harboe M, Mollnes TE.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15861-6. doi: 10.1073/pnas.0903613106. Epub 2009 Aug 26.

48.

[Placing pacemaker--no conclusive answer].

Haug B, Lappegård KT.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2619. Norwegian. No abstract available.

49.

The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent.

Lappegård KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, Mollnes TE.

J Biomed Mater Res A. 2008 Oct;87(1):129-35.

50.

Invited commentary.

Lappegard KT.

Ann Thorac Surg. 2007 Jan;83(1):152. No abstract available.

PMID:
17184650

Supplemental Content

Loading ...
Support Center